TheraRadar
← Back
Data updated: May 24, 2026

IVAX SUB TEVA PHARMS

Generics

IVAX SUB TEVA PHARMS is a generic drug manufacturer focused on Cardiovascular, Immunology, Dermatology.

1963
Since
109
Drugs
-
Trials
1
New Drugs (2yr)
Modality:

Key Drugs

Top revenue-generating and strategically important drugs approved in the last 15 years. These represent the company's core commercial portfolio.

No active drugs

Therapeutic Areas

Disease areas where this company has approved drugs and active pipeline. Weighted by commercial stage: approved drugs count most, followed by late-stage trials.

Cardiovascular 38%
9 drugs
Immunology 21%
5 drugs
Dermatology 17%
4 drugs
Infectious Disease 17%
4 drugs
Gastroenterology 8%
2 drugs

Pipeline Snapshot

Active clinical trials across all therapeutic areas. Data from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Cardiovascular pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling